Compare Stitch Fix Inc (SFIX) vs 10X Genomics Inc (TXG) Price & Performance

Stitch Fix (SFIX) trades at $2.73, up 2.25% today, but remains under pressure with a bearish technical signal. Recent Q4 2026 earnings showed a narrower loss than expected, but revenue missed estimates and weak FY2027 guidance triggered an 18% stock drop. The company is navigating a challenging consumer environment while leveraging AI personalization to boost engagement. Fundamentals show improving net loss margins, but negative ROE and ROA persist.

The outlook is cautious. While cost controls are improving losses, declining active clients and soft revenue guidance pose headwinds. Analyst consensus is a $3.40 price target with a 'Hold' bias. Key risks include execution on growth initiatives, high client acquisition costs, and ongoing legal investigations. The stock offers speculative appeal if turnaround gains traction, but near-term volatility is likely.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.